Zimmer Biomet Holdings (ZBH) has an average broker rating of 1.7, which is interpreted as a Buy, as rated by 22 equity analysts. Nonetheless, 13 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.
Zimmer Biomet Holdings (ZBH) has been rated by 14 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $135 and the lowest price target forecast is $105. The average forecast of all the analysts is $129 and the expected standard deviation is $8.34.
For the current week, the company shares have a recommendation consensus of Buy.
Zimmer Biomet Holdings (NYSE:ZBH): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $125.12 and $124.85 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $126.18. The buying momentum continued till the end and the stock did not give up its gains. It closed at $125.46, notching a gain of 0.30% for the day. The total traded volume was 1,085,675 . The stock had closed at $125.08 on the previous day.
Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc. is a musculoskeletal healthcare company. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company manages its operations through three geographic segments: the Americas, comprising principally of the United States and includes other North, Central and South American markets; Europe, comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions, such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers, and directly to dental practices and dental laboratories.